FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204098595> ?p ?o ?g. }

• W3204098595 endingPage "1069" @default.
• W3204098595 startingPage "1063" @default.
• W3204098595 abstract "As an expansion investigation of drug-drug interaction (DDI) from previous clinical trials, additional plasma endogenous metabolites were quantitated in the same subjects to further identify the potential biomarkers of organic anion transporter (OAT) 1/3 inhibition. In the single dose, open label, three-phase with fixed order of treatments study, 14 healthy human volunteers orally received 1000 mg probenecid alone, or 40 mg furosemide alone, or 40 mg furosemide at 1 hour after receiving 1000 mg probenecid on days 1, 8, and 15, respectively. Endogenous metabolites including kynurenic acid, xanthurenic acid, indo-3-acetic acid, pantothenic acid, <i>p</i>-cresol sulfate, and bile acids in the plasma were measured by liquid chromatography–tandem mass spectrometry. The C_max of kynurenic acids was significantly increased about 3.3- and 3.7-fold over the baseline values at predose followed by the treatment of probenecid alone or in combination with furosemide respectively. In comparison with the furosemide-alone group, the C_max and area under the plasma concentration–time curve (AUC) up to 12 hours of kynurenic acid were significantly increased about 2.4- and 2.5-fold by probenecid alone, and 2.7- and 2.9-fold by probenecid plus furosemide, respectively. The increases in C_max and AUC of plasma kynurenic acid by probenecid are comparable to the increases of furosemide C_max and AUC reported previously. Additionally, the plasma concentrations of xanthurenic acid, indo-3-acetic acid, pantothenic acid, and <i>p</i>-cresol sulfate, but not bile acids, were also significantly elevated by probenecid treatments. The magnitude of effect size analysis for known potential endogenous biomarkers demonstrated that kynurenic acid in the plasma offers promise as a superior addition for early DDI assessment involving OAT1/3 inhibition. <h3>SIGNIFICANCE STATEMENT</h3> This article reports that probenecid, an organic anion transporter (OAT) 1 and OAT3 inhibitor, significantly increased the plasma concentrations of kynurenic acid and several uremic acids in human subjects. Of those, the increases of plasma kynurenic acid exposure are comparable to the increases of furosemide by OAT1/3 inhibition. Effect size analysis for known potential endogenous biomarkers revealed that plasma kynurenic acid is a superior addition for early drug-drug interaction assessment involving OAT1/3 inhibition." @default.
• W3204098595 created "2021-10-11" @default.
• W3204098595 creator A5005260312 @default.
• W3204098595 creator A5011240907 @default.
• W3204098595 creator A5012391798 @default.
• W3204098595 creator A5058112913 @default.
• W3204098595 creator A5062288692 @default.
• W3204098595 creator A5069154460 @default.
• W3204098595 creator A5083206205 @default.
• W3204098595 creator A5087048002 @default.
• W3204098595 creator A5089124964 @default.
• W3204098595 creator A5089764461 @default.
• W3204098595 date "2021-10-01" @default.
• W3204098595 modified "2023-09-26" @default.
• W3204098595 title "Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition" @default.
• W3204098595 cites W107379563 @default.
• W3204098595 cites W1558276030 @default.
• W3204098595 cites W1588055561 @default.
• W3204098595 cites W1801619426 @default.
• W3204098595 cites W1988428106 @default.
• W3204098595 cites W2004082394 @default.
• W3204098595 cites W2005244160 @default.
• W3204098595 cites W2022868074 @default.
• W3204098595 cites W2041063533 @default.
• W3204098595 cites W2041599698 @default.
• W3204098595 cites W2062165080 @default.
• W3204098595 cites W2095930613 @default.
• W3204098595 cites W2096169020 @default.
• W3204098595 cites W2102006967 @default.
• W3204098595 cites W2114611192 @default.
• W3204098595 cites W2114997404 @default.
• W3204098595 cites W2139619607 @default.
• W3204098595 cites W2150073650 @default.
• W3204098595 cites W2152732346 @default.
• W3204098595 cites W2166438523 @default.
• W3204098595 cites W2339856074 @default.
• W3204098595 cites W2347062401 @default.
• W3204098595 cites W2515638948 @default.
• W3204098595 cites W2518662404 @default.
• W3204098595 cites W2520115765 @default.
• W3204098595 cites W2586590687 @default.
• W3204098595 cites W2588066480 @default.
• W3204098595 cites W2616878580 @default.
• W3204098595 cites W2737197622 @default.
• W3204098595 cites W2769871898 @default.
• W3204098595 cites W2788664869 @default.
• W3204098595 cites W2799486834 @default.
• W3204098595 cites W2896835015 @default.
• W3204098595 cites W2898268232 @default.
• W3204098595 cites W2982582313 @default.
• W3204098595 cites W2986770404 @default.
• W3204098595 cites W3045750033 @default.
• W3204098595 doi "https://doi.org/10.1124/dmd.121.000486" @default.
• W3204098595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34599018" @default.
• W3204098595 hasPublicationYear "2021" @default.
• W3204098595 type Work @default.
• W3204098595 sameAs 3204098595 @default.
• W3204098595 citedByCount "5" @default.
• W3204098595 countsByYear W32040985952021 @default.
• W3204098595 countsByYear W32040985952022 @default.
• W3204098595 countsByYear W32040985952023 @default.
• W3204098595 crossrefType "journal-article" @default.
• W3204098595 hasAuthorship W3204098595A5005260312 @default.
• W3204098595 hasAuthorship W3204098595A5011240907 @default.
• W3204098595 hasAuthorship W3204098595A5012391798 @default.
• W3204098595 hasAuthorship W3204098595A5058112913 @default.
• W3204098595 hasAuthorship W3204098595A5062288692 @default.
• W3204098595 hasAuthorship W3204098595A5069154460 @default.
• W3204098595 hasAuthorship W3204098595A5083206205 @default.
• W3204098595 hasAuthorship W3204098595A5087048002 @default.
• W3204098595 hasAuthorship W3204098595A5089124964 @default.
• W3204098595 hasAuthorship W3204098595A5089764461 @default.
• W3204098595 hasBestOaLocation W32040985951 @default.
• W3204098595 hasConcept C104317684 @default.
• W3204098595 hasConcept C123584848 @default.
• W3204098595 hasConcept C149011108 @default.
• W3204098595 hasConcept C178790620 @default.
• W3204098595 hasConcept C185592680 @default.
• W3204098595 hasConcept C2776706248 @default.
• W3204098595 hasConcept C2776769776 @default.
• W3204098595 hasConcept C2776841986 @default.
• W3204098595 hasConcept C2777955127 @default.
• W3204098595 hasConcept C2779187253 @default.
• W3204098595 hasConcept C515207424 @default.
• W3204098595 hasConcept C55493867 @default.
• W3204098595 hasConcept C71924100 @default.
• W3204098595 hasConcept C98274493 @default.
• W3204098595 hasConceptScore W3204098595C104317684 @default.
• W3204098595 hasConceptScore W3204098595C123584848 @default.
• W3204098595 hasConceptScore W3204098595C149011108 @default.
• W3204098595 hasConceptScore W3204098595C178790620 @default.
• W3204098595 hasConceptScore W3204098595C185592680 @default.
• W3204098595 hasConceptScore W3204098595C2776706248 @default.
• W3204098595 hasConceptScore W3204098595C2776769776 @default.
• W3204098595 hasConceptScore W3204098595C2776841986 @default.
• W3204098595 hasConceptScore W3204098595C2777955127 @default.
• W3204098595 hasConceptScore W3204098595C2779187253 @default.
• W3204098595 hasConceptScore W3204098595C515207424 @default.

• next